Payment overview · 2025
General Payments
$416.51
16 reported records · 10 companies
Healthcare provider profile · identity verified
Larry Joe Russell, MD
Allopathic & Osteopathic Physicians|Family Medicine · HORSE SHOE, NC · NPI 1891772513
Verified facts
What the public records show
CMS Open Payments records show Larry Joe Russell, MD received $416.51 in general payments during 2025 across 16 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 37.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $158.01 | 37.9% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.41 | 11.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.44 | 9.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.54 | 9.0% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $27.13 | 6.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.43 | 6.1% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $22.95 | 5.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.81 | 5.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.01 | 4.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.78 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $416.51 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $158.01 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $37.54 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.54 | 2 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $27.13 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.43 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| NEXIUM Normalized: nexium |
Drug | AstraZeneca Pharmaceuticals LP | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 78 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1358 | 226 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1164 | 197 |
| Trazodone Hcl | Trazodone Hcl | 1080 | 196 |
| Gabapentin | Gabapentin | 967 | 151 |
| Eliquis | Apixaban | 939 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 903 | 146 |
| Xarelto | Rivaroxaban | 746 | 71 |
| Lisinopril | Lisinopril | 658 | 121 |
| Furosemide | Furosemide | 603 | 127 |
| Losartan Potassium | Losartan Potassium | 551 | 97 |
| Potassium Chloride | Potassium Chloride | 551 | 115 |
| Escitalopram Oxalate | Escitalopram Oxalate | 496 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 468 | 85 |
| Metformin Hcl | Metformin Hcl | 453 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 429 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 404 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 396 | 80 |
| Duloxetine Hcl | Duloxetine Hcl | 384 | 61 |
| Sertraline Hcl | Sertraline Hcl | 359 | 63 |
| Donepezil Hcl | Donepezil Hcl | 353 | 57 |
| Mirtazapine | Mirtazapine | 349 | 70 |
| Buspirone Hcl | Buspirone Hcl | 345 | 63 |
| Omeprazole | Omeprazole | 345 | 94 |
| Warfarin Sodium | Warfarin Sodium | 332 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 278 | 51 |
| Memantine Hcl | Memantine Hcl | 263 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 258 | 48 |
| Prednisone | Prednisone | 255 | 122 |
| Famotidine | Famotidine | 247 | 69 |
| Carvedilol | Carvedilol | 230 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 223 | 42 |
| Baclofen | Baclofen | 219 | 28 |
| Spironolactone | Spironolactone | 212 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 207 | 64 |
| Citalopram Hbr | Citalopram Hydrobromide | 203 | 34 |
| Simvastatin | Simvastatin | 198 | 38 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 197 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 194 | 38 |
| Allopurinol | Allopurinol | 173 | 33 |
| Lamotrigine | Lamotrigine | 168 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 167 | 101 |
| Aripiprazole | Aripiprazole | 156 | 18 |
| Divalproex Sodium | Divalproex Sodium | 156 | 37 |
| Finasteride | Finasteride | 153 | 25 |
| Latanoprost | Latanoprost | 153 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 35 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 152 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 145 | 18 |
| Myrbetriq | Mirabegron | 144 | 22 |
| Sodium Chloride | 0.9 % Sodium Chloride | 143 | 69 |
| Torsemide | Torsemide | 141 | 29 |
| Levetiracetam | Levetiracetam | 138 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 137 | 31 |
| Meloxicam | Meloxicam | 135 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 131 | 24 |
| Risperidone | Risperidone | 128 | 20 |
| Ceftriaxone | Ceftriaxone Sodium | 126 | 83 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 126 | 23 |
| Montelukast Sodium | Montelukast Sodium | 125 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 124 | 22 |
| Trulicity | Dulaglutide | 122 | 14 |
| Albuterol Sulfate | Albuterol Sulfate | 118 | 53 |
| Diclofenac Sodium | Diclofenac Sodium | 118 | 41 |
| Lactulose | Lactulose | 113 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 109 | 66 |
| Alendronate Sodium | Alendronate Sodium | 107 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 31 |
| Methenamine Hippurate | Methenamine Hippurate | 104 | 18 |
| Bupropion Xl | Bupropion Hcl | 103 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 101 | 26 |
| Azithromycin | Azithromycin | 99 | 65 |
| Hydralazine Hcl | Hydralazine Hcl | 98 | 24 |
| Levofloxacin | Levofloxacin | 97 | 53 |
| Jardiance | Empagliflozin | 96 | 18 |
| Januvia | Sitagliptin Phosphate | 95 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 94 | 18 |
| Propranolol Hcl | Propranolol Hcl | 92 | 21 |
| Entresto | Sacubitril/Valsartan | 90 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 90 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 32 |
| Bumetanide | Bumetanide | 84 | 19 |
| Glipizide | Glipizide | 82 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 80 | 51 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 18 |
| Farxiga | Dapagliflozin Propanediol | 78 | suppressed |
| Klor-Con 10 | Potassium Chloride | 78 | suppressed |
| Topiramate | Topiramate | 78 | 11 |
| Nystatin | Nystatin | 77 | 50 |
| Alprazolam | Alprazolam | 76 | 19 |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 76 | 43 |
| Ondansetron Hcl | Ondansetron Hcl | 74 | 46 |
| Benztropine Mesylate | Benztropine Mesylate | 73 | 13 |
| Digoxin | Digoxin | 73 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 73 | 36 |
| Fluconazole | Fluconazole | 72 | 42 |
| Methocarbamol | Methocarbamol | 72 | 14 |
| Cephalexin | Cephalexin | 71 | 42 |
| Celecoxib | Celecoxib | 70 | 20 |
| Ezetimibe | Ezetimibe | 70 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 12 |
| Clonidine Hcl | Clonidine Hcl | 66 | 22 |
| Propranolol Hcl Er | Propranolol Hcl | 66 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 65 | 11 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 65 | 24 |
| Budesonide | Budesonide | 64 | 16 |
| Ibuprofen | Ibuprofen | 64 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 63 | 11 |
| Ondansetron Odt | Ondansetron | 63 | 38 |
| Olanzapine | Olanzapine | 62 | 14 |
| Timolol Maleate | Timolol Maleate | 61 | 12 |
| Memantine Hcl Er | Memantine Hcl | 59 | suppressed |
| Lorazepam | Lorazepam | 57 | 27 |
| Movantik | Naloxegol Oxalate | 57 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 57 | suppressed |
| Relistor | Methylnaltrexone Bromide | 55 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 54 | suppressed |
| Glipizide Er | Glipizide | 53 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 53 | suppressed |
| Clonazepam | Clonazepam | 52 | 12 |
| Sucralfate | Sucralfate | 52 | 14 |
| Amoxicillin | Amoxicillin | 51 | 34 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 50 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 49 | 20 |
| Valacyclovir | Valacyclovir Hcl | 49 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 48 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 48 | 23 |
| Liothyronine Sodium | Liothyronine Sodium | 48 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 47 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 47 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 47 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 47 | 14 |
| Estradiol | Estradiol | 46 | 14 |
| Ozempic | Semaglutide | 46 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 46 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 45 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 45 | 29 |
| Clonidine | Clonidine | 44 | suppressed |
| Amantadine | Amantadine Hcl | 43 | suppressed |
| Acetic Acid | Acetic Acid | 42 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 41 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 41 | 21 |
| Midodrine Hcl | Midodrine Hcl | 41 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 40 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 39 | 13 |
| Nitroglycerin | Nitroglycerin | 39 | 22 |
| Probenecid | Probenecid | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | suppressed |
| Telmisartan | Telmisartan | 38 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 37 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 37 | suppressed |
| Ceftriaxone | Ceftriaxone In Is-Osm Dextrose | 36 | 25 |
| Linzess | Linaclotide | 36 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 35 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | 12 |
| Rexulti | Brexpiprazole | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 35 | 17 |
| Venlafaxine Hcl | Venlafaxine Hcl | 35 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 33 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 32 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 32 | 11 |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Vraylar | Cariprazine Hcl | 31 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 30 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 29 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 29 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 29 | 19 |
| Lithium Carbonate | Lithium Carbonate | 29 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 16 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Cefdinir | Cefdinir | 27 | 17 |
| Cholestyramine | Cholestyramine (With Sugar) | 27 | 12 |
| Diazepam | Diazepam | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 21 |
| Prazosin Hcl | Prazosin Hcl | 27 | suppressed |
| Rivastigmine | Rivastigmine | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 26 | suppressed |
| Levemir Flexpen | Insulin Detemir | 26 | suppressed |
| Methimazole | Methimazole | 26 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Austedo | Deutetrabenazine | 22 | suppressed |
| Erythromycin | Erythromycin Base | 22 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Dupixent Syringe | Dupilumab | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 13 |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Nyamyc | Nystatin | 21 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Ingrezza | Valbenazine Tosylate | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 19 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 12 |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Mirabegron Er | Mirabegron | 16 | suppressed |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 16 | 16 |
| Naproxen | Naproxen | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Clozapine | Clozapine | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 13 |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Pulmicort Flexhaler | Budesonide | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Azathioprine | Azathioprine | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Matzim La | Diltiazem Hcl | 12 | suppressed |
| Motegrity | Prucalopride Succinate | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $416.51 · 16 records | Bayer Healthcare Pharmaceuticals Inc. | BREZTRI, CAPLYTA, CT THROMBECTOMY SYSTEM KIT, Dexcom G6 Transmitter, FARXIGA, FLOWTRIEVER CATHETER, S, Kerendia, NEXIUM, Ozempic, QULIPTA, REXULTI, Rybelsus, UBRELVY, VYVGART HYTRULO, WATCHMAN Access System, Wegovy | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error